London Co. of Virginia Decreases Holdings in Enovis Corporation $ENOV

London Co. of Virginia lowered its stake in Enovis Corporation (NYSE:ENOV) by 6.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 447,376 shares of the company’s stock after selling 28,848 shares during the period. London Co. of Virginia owned approximately 0.78% of Enovis worth $14,030,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Humankind Investments LLC lifted its stake in shares of Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock valued at $217,000 after purchasing an additional 452 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Enovis by 6.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after purchasing an additional 495 shares during the last quarter. Wedge Capital Management L L P NC raised its holdings in Enovis by 0.3% during the 2nd quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company’s stock valued at $5,111,000 after buying an additional 498 shares during the period. Janney Montgomery Scott LLC lifted its position in Enovis by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 22,375 shares of the company’s stock worth $702,000 after buying an additional 593 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after buying an additional 621 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Wells Fargo & Company upped their price target on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.17.

Enovis Trading Down 5.0%

NYSE ENOV opened at $26.43 on Friday. The stock has a market cap of $1.51 billion, a PE ratio of -1.12 and a beta of 1.52. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.38. The company’s 50-day moving average price is $30.11 and its 200-day moving average price is $30.53. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. The company had revenue of $383.81 million during the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. Equities research analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John Kleckner bought 2,468 shares of the stock in a transaction on Tuesday, November 25th. The stock was purchased at an average price of $30.32 per share, with a total value of $74,829.76. Following the completion of the acquisition, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 2.70% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.